922 related articles for article (PubMed ID: 16863484)
1. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
[TBL] [Abstract][Full Text] [Related]
2. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Abraham WT; Adams KF; Fonarow GC; Costanzo MR; Berkowitz RL; LeJemtel TH; Cheng ML; Wynne J; ;
J Am Coll Cardiol; 2005 Jul; 46(1):57-64. PubMed ID: 15992636
[TBL] [Abstract][Full Text] [Related]
3. Perioperative nesiritide versus milrinone in high-risk coronary artery bypass graft patients.
Brackbill ML; Stam MD; Schuller-Williams RV; Dhavle AA
Ann Pharmacother; 2007 Mar; 41(3):427-32. PubMed ID: 17311834
[TBL] [Abstract][Full Text] [Related]
4. Intravenous nesiritide in acute heart failure.
Knox MA; Dancy T; Mook W; Pschirer JJ
Am J Ther; 2005; 12(3):233-7. PubMed ID: 15891267
[TBL] [Abstract][Full Text] [Related]
5. Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure.
Aronson D; Burger AJ
Am Heart J; 2004 Nov; 148(5):e16. PubMed ID: 15523294
[TBL] [Abstract][Full Text] [Related]
6. Outcomes associated with nesiritide administration for acute decompensated heart failure in the emergency department observation unit: a single center experience.
Styron JF; Jois-Bilowich P; Tallman T; Emerman C; Starling RC; Frank Peacock W
Congest Heart Fail; 2009; 15(3):103-7. PubMed ID: 19522957
[TBL] [Abstract][Full Text] [Related]
7. Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact.
Yamani MH; Haji SA; Starling RC; Kelly L; Albert N; Knack DL; Young JB
Am Heart J; 2001 Dec; 142(6):998-1002. PubMed ID: 11717603
[TBL] [Abstract][Full Text] [Related]
8. Rationale, design, and methods for the Transplant-Eligible MAnagement of Congestive Heart Failure (TMAC) trial: a multicenter clinical outcomes trial using nesiritide for TMAC.
Mehra MR; McCluskey T; Barr M; Bourge RC; Jessup ML; Mancini D; Radovancevic B; Rayburn B; Taylor DO; Lilly-Hersley J; Linde P
Am Heart J; 2007 Jun; 153(6):932-40. PubMed ID: 17540193
[TBL] [Abstract][Full Text] [Related]
9. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
Kurien S; Warfield KT; Wood CM; Miller WL
Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223
[TBL] [Abstract][Full Text] [Related]
10. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study.
Burger AJ; Horton DP; LeJemtel T; Ghali JK; Torre G; Dennish G; Koren M; Dinerman J; Silver M; Cheng ML; Elkayam U;
Am Heart J; 2002 Dec; 144(6):1102-8. PubMed ID: 12486437
[TBL] [Abstract][Full Text] [Related]
11. Dobutamine Therapy is Associated with Worse Clinical Outcomes Compared with Nesiritide Therapy for Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.
Wang XC; Zhu DM; Shan YX
Am J Cardiovasc Drugs; 2015 Dec; 15(6):429-37. PubMed ID: 26123415
[TBL] [Abstract][Full Text] [Related]
12. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure.
Silver MA; Horton DP; Ghali JK; Elkayam U
J Am Coll Cardiol; 2002 Mar; 39(5):798-803. PubMed ID: 11869844
[TBL] [Abstract][Full Text] [Related]
13. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
de Lissovoy G; Fraeman K; Salon J; Chay Woodward T; Sterz R
J Med Econ; 2008; 11(3):415-29. PubMed ID: 19450096
[TBL] [Abstract][Full Text] [Related]
14. Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE.
Peacock WF; Fonarow GC; Emerman CL; Mills RM; Wynne J; ;
Cardiology; 2007; 107(1):44-51. PubMed ID: 16741357
[TBL] [Abstract][Full Text] [Related]
15. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial.
Aranda JM; Schofield RS; Pauly DF; Cleeton TS; Walker TC; Monroe VS; Leach D; Lopez LM; Hill JA
Am Heart J; 2003 Feb; 145(2):324-9. PubMed ID: 12595851
[TBL] [Abstract][Full Text] [Related]
16. Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure.
Lewis DA; Gurram NR; Abraham WT; Akers WS
Am J Health Syst Pharm; 2003 Aug; 60 Suppl 4():S16-20. PubMed ID: 12966902
[TBL] [Abstract][Full Text] [Related]
17. Controversy and conflict in the treatment of acute decompensated heart failure: limited role for nesiritide.
Noviasky JA
Pharmacotherapy; 2007 May; 27(5):626-32. PubMed ID: 17461696
[TBL] [Abstract][Full Text] [Related]
18. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
[TBL] [Abstract][Full Text] [Related]
19. Nesiritide Therapy Is Associated With Better Clinical Outcomes Than Dobutamine Therapy in Heart Failure.
Kong LG; Wang CL; Zhao D; Wang B
Am J Ther; 2017; 24(2):e181-e188. PubMed ID: 26164026
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive ventilation outcomes in 2,430 acute decompensated heart failure patients: an ADHERE Registry Analysis.
Tallman TA; Peacock WF; Emerman CL; Lopatin M; Blicker JZ; Weber J; Yancy CW;
Acad Emerg Med; 2008 Apr; 15(4):355-62. PubMed ID: 18370990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
